In order to control the cell surface molecule specificity of the αCD33-mAB-P/P carrier antibody for the nanocarrier efficacy, we applied αCD33-mAB-P/P-siRNA nanocarriers to cell lines that do not express CD33, for instance A549 non-small cell lung cancer (NSCLC) cells as well as OCI-Ly19 lymphoma cells (Additional file 1: Figure S1 E–F). This evidence concerns the gene CD33 and lymphoma.